**Supplemental Table S1**: Overview about administered antiplatelet medication in the participating centers

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Center A | Center B | Center C | Center D |
| Prior to stenting | weight-adapted bolus of tirofiban followed by a continuous IV infusion for 24 hours | acetylsalicylic acid 500 mg | weight-adapted bolus of tirofiban followed by a continuous IV infusion for 12 hours | half of the recommended bolus dose (0.125 mg/kg body weight) of abciximab |
| After the procedure |  |  |  | 300 mg acetylsalicylic acid,  300 mg clopidogrel |
| After control CT scan\* | 500 mg acetylsalicylic acid,  300 mg clopidogrel | 100 mg acetylsalicylic acid,  450 mg clopidogrel | 500 mg acetylsalicylic acid,  300 mg clopidogrel |  |
| Dual antiplatelet | 6 months  100 mg acetylsalicylic acid,  75 mg clopidogrel  Life-long  100 mg acetylsalicylic acid | 6 weeks  100 mg acetylsalicylic acid,  75 mg clopidogrel  Life-long  100 mg acetylsalicylic acid | 3 months  100 mg acetylsalicylic acid,  75 mg clopidogrel  Life-long  100 mg acetylsalicylic acid | 3 month  75 mg clopidogrel  6 month  acetylsalicylic acid |

\* when routine follow-up CT scan did not reveal a significant hematoma